Acutaas Chemicals Ltd

Acutaas Chemical Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Acutaas Chemicals Ltd

₹ 3,497 3.03%
13 Jul 2:57 p.m.
amiorganics.com BSE: 543349 NSE: ACUTAAS
About

Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]

Key Points

Business Overview [1] [2]
The company is a specialty chemicals manufacturer with a diversified portfolio of over 610 products, serving industries such as pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. Its core expertise lies in the research-driven development and manufacturing of advanced pharmaceutical intermediates for regulated and generic APIs, as well as intermediates for New Chemical Entities (NCEs). It is also expanding into high-value specialty chemicals catering to emerging applications, including battery materials, semiconductors, and next-generation electronics.

Website BSE NSE
  • Market Cap ₹ 28,630 Cr.
  • Current Price ₹ 3,497
  • High / Low ₹ 3,740 / 1,124
  • Stock P/E 80.4
  • Book Value ₹ 202
  • Dividend Yield 0.04 %
  • ROCE 31.6 %
  • ROE 24.0 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 45.8% CAGR over last 5 years

Cons

  • Stock is trading at 17.0 times its book value
  • Promoter holding has decreased over last 3 years: -6.75%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty500 Shariah Nifty Alpha 50

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
186 154 172 166 225 177 247 275 308 207 306 393 433
146 120 148 140 182 147 198 206 224 156 211 243 249
Operating Profit 41 34 25 27 43 30 49 69 85 51 95 151 184
OPM % 22% 22% 14% 16% 19% 17% 20% 25% 28% 25% 31% 38% 42%
-0 1 -30 3 1 1 8 2 6 16 10 5 11
Interest 1 1 1 3 2 4 0 1 1 1 1 1 1
Depreciation 3 4 4 4 5 6 7 6 7 8 8 10 10
Profit before tax 37 31 -10 24 37 20 50 63 83 58 96 145 184
Tax % 26% 28% 71% 25% 31% 26% 25% 28% 24% 24% 25% 27% 27%
27 22 -17 18 26 15 38 45 63 44 72 106 134
EPS in Rs 3.73 2.71 -2.55 2.27 3.41 1.71 4.56 5.49 7.63 5.41 8.82 13.19 16.09
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
160 188 239 240 341 520 617 717 1,007 1,339
137 157 196 198 260 415 493 589 775 859
Operating Profit 23 31 42 42 80 105 123 128 232 480
OPM % 14% 16% 18% 17% 24% 20% 20% 18% 23% 36%
0 3 0 2 1 3 4 -25 17 42
Interest 3 3 5 6 6 6 2 6 6 3
Depreciation 1 2 3 4 4 10 12 16 27 36
Profit before tax 19 28 35 35 72 91 112 82 216 483
Tax % 35% 35% 34% 21% 25% 21% 26% 41% 26% 26%
12 18 23 27 54 72 83 49 160 356
EPS in Rs 40.17 61.67 11.10 13.08 8.57 9.87 11.43 5.80 19.38 43.51
Dividend Payout % 0% 0% 0% 0% 0% 15% 13% 26% 8% 6%
Compounded Sales Growth
10 Years: %
5 Years: 32%
3 Years: 30%
TTM: 33%
Compounded Profit Growth
10 Years: %
5 Years: 46%
3 Years: 62%
TTM: 124%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 79%
1 Year: 197%
Return on Equity
10 Years: 20%
5 Years: 18%
3 Years: 18%
Last Year: 24%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 2 2 10 10 32 36 36 37 41 41
Reserves 37 56 72 101 135 486 558 637 1,269 1,613
27 44 54 59 137 1 4 217 13 36
43 54 77 61 110 136 169 205 227 295
Total Liabilities 109 155 213 232 413 659 767 1,096 1,549 1,984
28 32 79 85 186 205 259 427 570 745
CWIP 11 30 2 12 0 3 30 125 130 332
Investments 1 3 2 2 1 2 2 0 0 0
68 91 131 133 225 450 477 543 848 907
Total Assets 109 155 213 232 413 659 767 1,096 1,549 1,984

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
29 8 15 27 28 -12 66 125 118 292
-19 -25 -21 -24 -101 -121 -33 -365 -224 -266
-7 15 6 0 72 140 -12 239 261 4
Net Cash Flow 3 -2 -0 3 -1 8 20 -1 156 30
Free Cash Flow 10 -16 -7 6 -77 -46 -31 -155 -76 -36
CFO/OP 153% 53% 68% 85% 52% 10% 73% 116% 71% 84%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 83 97 116 86 129 115 136 105 105 99
Inventory Days 76 89 95 148 123 150 131 139 119 149
Days Payable 148 154 168 146 172 158 157 119 103 99
Cash Conversion Cycle 11 31 43 88 80 107 111 125 121 149
Working Capital Days 46 64 28 34 51 141 139 80 123 116
ROCE % 38% 34% 27% 33% 24% 21% 16% 20% 32%

Insights

In beta
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Export Share of Revenue
%

Log in to view insights

Please log in to see hidden values.

Login
Pharmaceutical Intermediates Revenue Share
%
Number of Countries Served
count
Number of Customers
count
Number of Products Invoiced
count
Process Patents
count
Total Installed Capacity
KL

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
39.41% 38.93% 39.91% 39.91% 35.98% 35.97% 35.96% 35.96% 32.66% 32.66% 32.66% 32.66%
6.73% 7.15% 11.66% 8.98% 12.93% 13.87% 15.52% 16.48% 16.94% 16.84% 16.67% 19.48%
5.12% 5.95% 7.58% 6.80% 14.81% 19.93% 20.23% 18.31% 22.38% 22.59% 21.70% 19.60%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
48.74% 47.97% 40.85% 44.31% 36.28% 30.24% 28.27% 29.22% 28.00% 27.89% 28.96% 28.24%
No. of Shareholders 70,35272,89783,34495,78490,98793,39495,7561,14,0601,19,8901,08,6641,10,3631,12,939

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls